Future aspects of CDK5 in prostate cancer: From pathogenesis to therapeutic implications

Muhammet Oner, Eugene Lin, Mei Chih Chen, Fu Ning Hsu, G. M. Shazzad Hossain Prince, Kun Yuan Chiu, Chieh Lin Jerry Teng, Tsung Ying Yang, Hsin Yi Wang, Chia Herng Yue, Ching Han Yu, Chih Ho Lai, Jer Tsong Hsieh, Ho Lin*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


Cyclin-dependent kinase 5 (CDK5) is a unique member of the cyclin-dependent kinase family. CDK5 is activated by binding with its regulatory proteins, mainly p35, and its activation is essential in the development of the central nervous system (CNS) and neurodegeneration. Recently, it has been reported that CDK5 plays important roles in regulating various biological and pathological processes, including cancer progression. Concerning prostate cancer, the androgen receptor (AR) is majorly involved in tumorigenesis, while CDK5 can phosphorylate AR and promotes the proliferation of prostate cancer cells. Clinical evidence has also shown that the level of CDK5 is associated with the progression of prostate cancer. Interestingly, inhibition of CDK5 prevents prostate cancer cell growth, while drug-triggered CDK5 hyperactivation leads to apoptosis. The blocking of CDK5 activity by its small interfering RNAs (siRNA) or Roscovitine, a pan-CDK inhibitor, reduces the cellular AR protein level and triggers the death of prostate cancer cells. Thus, CDK5 plays a crucial role in the growth of prostate cancer cells, and AR regulation is one of the important pathways. In this review paper, we summarize the significant studies on CDK5-mediated regulation of prostate cancer cells. We propose that the CDK5–p35 complex might be an outstanding candidate as a diagnostic marker and potential target for prostate cancer treatment in the near future.

Original languageEnglish
Article number3881
JournalInternational Journal of Molecular Sciences
Issue number16
StatePublished - 02 08 2019

Bibliographical note

Publisher Copyright:
© 2019 by the authors. Licensee MDPI, Basel, Switzerland.


  • Androgen receptor (AR)
  • Cyclin-dependent kinase 5 (CDK5)
  • P35
  • Prostate cancer


Dive into the research topics of 'Future aspects of CDK5 in prostate cancer: From pathogenesis to therapeutic implications'. Together they form a unique fingerprint.

Cite this